PCM
BMY.RT

Prelude Capital Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Prelude Capital Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-291,332
Closed -$201K – 1958
2020
Q4 		$201K Buy
291,332
+52,946
+22% +$113K 0.01% 1120
2020
Q3 		$536K Sell
238,386
-88,557
-27% -$253K 0.03% 427
2020
Q2 		$1.17M Buy
326,943
+180,427
+123% +$651K 0.06% 275
2020
Q1 		$557K Sell
146,516
-63,274
-30% -$208K 0.04% 311
2019
Q4 		$631K Buy
+209,790
New +$546K 0.02% 499

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Prelude Capital Management's BMY.RT Position: Q1 2021 in Review

Prelude Capital Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 291,332 shares — an estimated $201K sold.

Prelude Capital Management first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $1.17M in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Prelude Capital Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Prelude Capital Management sold 291,332 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $201K.
  • Prelude Capital Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Prelude Capital Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1.17M in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Prelude Capital Management's 13F filing for Q1 2021, filed 17 May 2021.